Zenith Technologies appoints MES lead
James O’Brien will lead the company's manufacturing execution system business to its next phase of growth.
Global life science technology firm, Zenith Technologies, has appointed James O’Brien to lead its manufacturing execution system (MES) business to its next phase of growth.
During the past 5 years, Zenith Technologies has strategically grown its MES offering globally to meet growing demand for technology-based manufacturing efficiency programs in the life science sector.
In his role as MES business unit lead, James will use his background in software development, consultancy and technology implementation to continue to develop Zenith Technologies as a world leader in the provision of MES solutions and services to the life science industry.
Zenith Technologies assists pharmaceutical and medical device manufacturers with the implementation of MES solutions, providing on-the-ground support. James will be focused on forming further collaborations in the industry to support life science companies with the transition to MES and automated systems.
Commenting on the appointment, Jim Lehane, director at Zenith Technologies, said: “James has worked with us as a senior MES engineer for a number of years, supporting some of the world’s leading pharmaceutical companies with global automation projects. In his new role as MES business unit lead, James will drive Zenith Technologies forward to further success in the US and Europe, leveraging our global presence, skilled engineers and world-class implementation and support services.”
James’ appointment comes as MES technology is being adopted by the life science industry at a faster rate than any other vertical market. To support demand, the firm recently announced a partnership with MES software provider Werum IT Solutions.
Jim continued: “It’s an exciting time for our company, as pharmaceutical and medical device manufacturers are recognising the benefits of MES and adoption is increasing at a steady rate. In particular, we are experiencing increasing demand in the US market, which has led us to open two new offices in Oakland and San Diego.”
Based in Bluebell, PA, James will lead Zenith Technologies’ team of engineers in 16 offices globally to support clients with their manufacturing enterprise solution needs.
He said: “MES technology can dramatically improve productivity during manufacturing, however there are a number of challenges associated with its implementation. It is our goal to assist companies with the transition to MES systems so they can realise the benefits with minimal disruption to their operations.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance